The Benefit of Hydrogen Gas as an Adjunctive Therapy for Chronic Obstructive Pulmonary Disease.
Shih-Feng Liu, Chin-Ling Li, Hui-Ching Lee, Hui-Chuan Chang, Jui-Fang Liu, Ho-Chang Kuo · Medicina (Kaunas, Lithuania) · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 6 patients with chronic obstructive pulmonary disease (COPD), however, no significant differences were observed in lung function, DLCO, sleep quality, and 6 MWT before and after hydrogen therapy. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 6 patients with chronic obstructive pulmonary disease (COPD). However, no significant differences were observed in lung function, DLCO, sleep quality, and 6 MWT before and after hydrogen therapy.
What the Researchers Studied
The researchers studied 6 patients with chronic obstructive pulmonary disease (COPD). The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 73% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 73% source-reported H₂ gas concentration; reported treatment duration: 30 min. However, no significant differences were observed in lung function, DLCO, sleep quality, and 6 MWT before and after hydrogen therapy. The authors concluded that adjuvant therapy with hydrogen gas demonstrated symptom improvements in specific COPD patients, and no significant adverse effects were observed in any of the patients. Recent studies suggest that hydrogen gas possesses anti-inflammatory, antioxidant, and anti-apoptotic properties.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 6 patients with chronic obstructive pulmonary disease (COPD). The study used a human clinical study. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 73% source-reported H₂ gas concentration. The reported treatment duration was 30 min.
Limitations and Safety
Reported limitations: Diagnosis criteria include a fixed ratio of FEV1/FVC less than 0.7 after bronchodilator inhalation, indicating persistent airflow limitation.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.